Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK4382276A (mRNA Flu) Phase 1/2
NCT05823974Phase 2Completed
- Sponsor
- GSK
- Start
- Apr 2023
- Primary completion
- Jul 2024
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 4
01
Overview
A Phase 2 trial of GSK4382276A in influenza, sponsored by GSK. Started Apr 2023; status: completed.
02
Drugs
GSK4382276A
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05823974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05823974.